Patients, Not Patents, Will Shape Life Science

3 min read

A pencil and watercolor drawing of a patient that runs away from a stressed posh doctor with a syringe in his hand

Why M&A strategy focusing on selling low-margin business inhibits innovation, lowers entry barriers, dilutes expertise, and weakens patient ties In the last years, Mergers and Acquisitions strategies in life science have reflected the desire of large organizations to adapt to changing market conditions and to focus on areas with a higher potential for size and profit growth. To increase shareholder value, pharmaceutical companies have expanded into precision medicine, oncology, cell and gene therapies, and other high-potential fields. Generally speaking, they adopted a well-oiled two-step approach:  A divestment of their over-the-counter (OTC) and generic divisions, which are typically lower-margin and less innovative…...

This article is free to read

Login to read the full article


By subscribing to our main site, you will also be subscribed to DDIntel - our regular letter showcasing our featured articles and applications.

Flavio Aliberti Flavio Aliberti brings with him a 23-year track record in consulting around business intelligence, change management, strategy, M&A transformation, IT and SOX auditing for high regulated domains, like Insurance, Airlines, Trade Associations, Automotive, and Pharma. He holds an MSc in Space Aeronautic Engineering from the University of Naples and an MSc in Advanced Information Technology and Business Management from the University of Wales.